3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Stomach Neoplasms
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Sunitinib
16
Imatinib Mesylate
13
nilotinib
8
ripretinib
4
regorafenib
4
avapritinib
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
pembrolizumab
2
Bevacizumab
2
trametinib
1
tinostamustine
1
spartalizumab
1
romidepsin
1
ponatinib
1
pazopanib
1
palbociclib
1
olaratumab
1
guadecitabine
1
ferric carboxymaltose
1
epacadostat
1
dabrafenib
1
cediranib
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sorafenib
1
STA 9090
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Stromal Tumors
×
pemigatinib
×
Clear all
No trials found.